Friday, July 10, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “ponatinib” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 10
Total indexed 20,548
Sponsors 1,771

Quick answer

Showing 10 pipeline programs matching "ponatinib" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

10 results for “ponatinib” Back to intelligence hub

Search results

  1. Ponatinib

    Takeda

    Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

    phase 3 small molecule active

    1 trial
  2. Ponatinib 30 mg QD

    Takeda

    Chronic Phase Chronic Myeloid Leukemia

    phase 3 small molecule terminated

    1 trial
  3. Ponatinib-3001

    Takeda

    Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial
  4. Ponatinib

    Takeda

    Myeloid Leukemia, Chronic, Chronic Phase

    phase 2 small molecule completed

    1 trial
  5. Ponatinib

    Takeda

    GIST

    phase 2 small molecule completed

    1 trial
  6. Ponatinib

    Takeda

    Chronic Myeloid Leukemia

    phase 2 small molecule completed

    1 trial
  7. Ponatinib

    Takeda

    Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)

    phase 2 small molecule terminated

    1 trial
  8. Ponatinib

    Cardiff Oncology

    Acute Lymphoblastic Leukemia, Adult

    phase 2 small molecule active

    1 trial
  9. ponatinib - Phase 1

    Takeda

    Chronic Myeloid Leukemia (CML)

    phase 2 small molecule completed

    1 trial
  10. Ponatinib

    Takeda

    Chronic Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.